Mutations in RBM20 (RNA-binding motif protein 20) cause a clinically aggressive form of dilated cardiomyopathy, with an increased risk of malignant ventricular arrhythmias. RBM20 is a splicing factor that targets multiple pivotal cardiac genes, such as Titin (TTN) and CAMK2D (calcium/calmodulin-dependent kinase II delta). Aberrant TTN splicing is thought to be the main determinant of RBM20-induced dilated cardiomyopathy, but is not likely to explain the increased risk of arrhythmias. Here, we investigated the extent to which RBM20 mutation carriers have an increased risk of arrhythmias and explore the underlying molecular mechanism.
RESULTS:
Sustained ventricular arrhythmias were more frequent in human RBM20 mutation carriers than in TTN mutation carriers (44% versus 5%, respectively, P=0.006). Splicing events that affected Ca 2+ -and ion-handling genes were enriched in Rbm20 KO mice, most notably in the genes CamkIIδ and RyR2. Aberrant splicing of CamkIIδ in Rbm20 KO mice resulted in a remarkable shift of CamkIIδ toward the δ-A isoform that is known to activate the L-type Ca 2+ current (I Ca,L ). In line with this, we found an increased I Ca,L , intracellular Ca 2+ overload and increased sarcoplasmic reticulum Ca 2+ content in Rbm20 KO myocytes. In addition, not only complete loss of Rbm20, but also heterozygous loss of Rbm20 increased spontaneous sarcoplasmic reticulum Ca 2+ releases, which could be attenuated by treatment with the I Ca,L antagonist verapamil.
CONCLUSIONS:
We show that loss of Rbm20 disturbs Ca 2+ handling and leads to more proarrhythmic Ca 2+ releases from the sarcoplasmic reticulum. Patients that carry a pathogenic RBM20 mutation have more ventricular arrhythmias despite a similar left ventricular function, in comparison with patients with a TTN mutation. Our experimental data suggest that RBM20 mutation carriers may benefit from treatment with an I Ca,L blocker to reduce their arrhythmia burden.
M
utations in the gene encoding RBM20 (RNAbinding motif protein 20) are known to cause dilated cardiomyopathy (DCM). [1] [2] [3] In fact, disease-causing mutations in RBM20 are relatively often found in familial DCM, because it accounts for ≈3% of the familial DCM cases. 4 Recent studies suggest that loss of RBM20 causes DCM by missplicing of the gene Titin (TTN). 5, 6 TTN is a giant sarcomeric protein that acts as a molecular spring in the sarcomere and, as such, defines the passive stiffness of the cardiomyocyte. Loss of RBM20 leads to aberrant splicing of TTN, reflected by increased expression of very large and compliant TTN isoforms in the heart, which is believed to underlie the DCM phenotype in RBM20 mutation carriers. However, clinical observations challenge the idea that mutations in RBM20 cause DCM only via dysfunctional TTN. RBM20 mutation carriers are known to present with a clinically aggressive form of DCM, associated with young age at diagnosis, fast progression of heart failure, increased risk of arrhythmias, and high mortality, 1, 2, 4 whereas TTN mutations are not associated with such an aggressive clinical course. 7, 8 RBM20 is a heart-and skeletal muscle-enriched splicing factor that controls tissue-specific isoform expression of many other genes besides TTN, including sarcomeric genes such myomesin 1, but also Ca 2+ -and ion-handling genes such as CAMK2D (calcium/calmodulin-dependent kinase II-delta) and RYR2 (ryanodine receptor 2). 5, 6 In that regard, it is of interest that human RBM20 mutation carriers present with an increased risk of arrhythmias, which is also observed in Rbm20-deficient rats. 4, 5 Taken together, this indicates that the missplicing of TTN alone is unlikely to fully explain the severe heart failure phenotype found in RBM20 mutation carriers, and that additional RBM20 targets may be of clinical importance. Indeed, in vitro analysis of cardiomyocytes derived from induced pluripotent stem cells of an RBM20 mutation carrier recently provided the first evidence that Rbm20 regulates Ca 2+ handling. 9 Here, we investigated the underlying mechanism of arrhythmias in RBM20 mutation carriers by using Rbm20 knockout (KO) mice and performing electrophysiological studies and Ca 2+ measurements. We recorded L-type Ca 2+ current (I Ca,L ) in wild-type (WT) and Rbm20 KO cardiomyocytes, and found an almost 2-fold increase in current density. Ca 2+ measurements revealed a severe intracellular Ca 2+ overload, and a propensity to spontaneous Ca 2+ releases from the sarcoplasmic reticulum (SR) in both heterozygous and homozygous Rbm20 KO cardiomyocytes. Blockade of I Ca,L with verapamil rescued the Ca 2+ releases from the SR, indicating that increased I Ca,L density is, at least in part, responsible for Ca 2+ overload in Rbm20 KO cells. Our data indicate that this disturbed Ca 2+ handling induced by dysfunctional Rbm20 underlies the increased risk of arrhythmias in RBM20 mutation carriers, and therefore this study provides new avenues to treat arrhythmias in RBM20 mutation carriers.
METHODS
The data, analytic methods, and study materials will be made available on reasonable request to other researchers for purposes of reproducing the results or replicating the procedure. Extended methods are given in File I in the online-only Data Supplement.
Patient Inclusion
The genetic test results of all patients with (suspected) DCM who were referred to the Department of Clinical Genetics of the Academic Medical Center (Amsterdam, The Netherlands) between 2005 and 2016 were retrospectively reviewed. All patients with a (likely) pathogenic variant in the RBM20 gene (n=18) or the TTN gene (n=22) and no other variants in genes associated with DCM were included. Additional information on patient inclusion can be found in File I in the online-only Data Supplement, and the mutations included in this study can be found in Table I in the online-only Data Supplement. Informed consent was obtained from all individuals, and the study conformed to the ethical guidelines of the 1975 Declaration of Helsinki.
Rbm20 KO Mice
Rbm20 KO mice were previously generated. 10 All animal studies were approved by the Institutional Animal Care and Use Committee of the University of Amsterdam, and in accordance with the guidelines of this institution and Directive 2010/63/EU of the European Parliament.
Clinical Perspective
What Is New?
• 
What Are the Clinical Implications?
• RBM20 mutation carriers may benefit from treatment with an L-type Ca 2+ current blocker to reduce their arrhythmia burden.
• RBM20 mutation carriers should be closely monitored for potential electric disturbances and cardiac arrhythmias, even in the early stages of the disease.
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Ca
2+ Measurements
Left ventricular cardiomyocytes from 8-to 12-week-old WT, heterozygous (+/-), and homozygous (-/-) Rbm20 KO mice were isolated by enzymatic dissociation on a Langendorff setup and loaded with the Ca
2+
-sensitive dye Indo-1-AM (Molecular Probes), and Ca 2+ transients were measured as previously described.
11
Cellular Electrophysiology
Action potentials (APs) and I Ca,L were recorded in isolated left ventricular (LV) cardiomyocytes from 8-to 12-week-old WT and Rbm20 KO mice at 36±0.2°C using an Axopatch 200B Amplifier (Molecular Devices). Voltage control, data acquisition, and analysis were realized with custom software, and potentials were corrected for the calculated liquid junction potentials. 12 Cell membrane capacitance (C m ) was calculated by dividing the time constant of the decay of the capacitive transient after a -5 mV voltage step from -40 mV by the series resistance. Signals were low-pass filtered with a cutoff of 5 kHz and digitized at 40 and 10 kHz for APs and I Ca,L , respectively. Series resistance was compensated by ≥80%.
Statistical Analysis
Data are presented as mean±SEM, and were analyzed with appropriate statistical tests, as indicated in the respective figure legends. A value of P<0.05 was considered statistically significant.
RESULTS
Increased Prevalence of Malignant Ventricular Arrhythmias in RBM20 Mutation Carriers
Patients with heterozygous RBM20 mutations present with DCM, but often also experience cardiac arrhythmias. We compared the arrhythmia burden of patients who have DCM with RBM20 mutations (n=18) with patients who have DCM with TTN mutations (n=22) ( Table) . Because TTN is the most prominently studied target of RBM20, and is considered the main determinant of the DCM phenotype of RBM20 mutation carriers, we used patients who have DCM with TTN mutations as a reference group. Both groups had similarly decreased LV chamber function (LV ejection fraction RBM20vsTTN , 37±17 versus 37±13), dilation of the LV (LV end-diastolic diameter RBM20vsTTN , 60±11 versus 59±9 and LV end-diastolic volume RBM20vsTTN , 269±92 versus 246±73), and similar ECG timing intervals (Table) . Despite comparable cardiac function and remodeling in both patient groups, RBM20 mutation carriers experienced more malignant ventricular arrhythmias, because 44% of the RBM20 mutation carriers had sustained ventricular arrhythmias (ie, sustained/symptomatic ventricular tachycardia or ventricular fibrillation), in comparison with only 5% in the TTN group (P=0.006). The increased risk of arrhythmias was also reflected by the increased number of internal cardioverter defibrillator implantations in the RBM20 group (internal cardioverter defibrillator RBM20vsTTN , 61% versus 9%, P=0.002). There were no differences in the pharmacological treatment of patients with RBM20 mutations and patients with TTN mutations. Finally, RBM20 mutation carriers more often tended to have a familial history of sudden cardiac death (sudden cardiac death RBM20vsTTN , 72% versus 36%, P=0.052). In conclusion, these data indicate that patients with RBM20 mutations have an increased risk of malignant ventricular arrhythmias in comparison with TTN mutation carriers, even though cardiac dilation and function are comparable in both patient groups. This also suggests that the cardiac pathology of RBM20 mutation carriers is only partly explained by altered TTN function, and that other factors contribute to the arrhythmia susceptibility.
Characterization of Rbm20 KO Mice
To investigate the molecular mechanisms underlying the increased risk of arrhythmias in RBM20 mutation carriers, we used Rbm20 KO mice that were previously generated by targeted disruption of exon 4 and 5 of the Rbm20 gene ( Figure 1A) . 10 Rbm20 KO mice were born in normal Mendelian ratios, were viable, and did not exhibit obvious abnormalities. We validated the loss of the targeted Rbm20 allele by quantitative polymerase chain reaction (all primer sequences can be found in Table II in the online-only Data Supplement), and observed an ≈50% reduction of Rbm20 mRNA in Rbm20 +/-hearts and a complete loss of Rbm20 mRNA in Rbm20 -/-hearts ( Figure 1B ). Quantitative polymerase chain reaction analysis of the stress markers atrial natriuretic factor and brain natriuretic factor revealed an upregulation of both markers in the hearts of Rbm20 -/-mice, but not in Rbm20 +/-mice ( Figure 1C and 1D) . Loss of Rbm20 resulted in disrupted splicing of Ttn and Ldb3 (LIM-domain binding 3) in the hearts of Rbm20 +/-and Rbm20 -/-mice ( Figure 1E ). This recapitulates previously described splicing effects of Rbm20 deficiency in mice and rats.
5,13
Next, we investigated the cardiac function and morphology of these mice. Heart weight/body weight ratios were not different between WT, Rbm20 +/-, and Rbm20 -/-mice ( Figure 1F ), but M-mode echocardiography revealed decreased fractional shortening and increased systolic diameters in both Rbm20 +/-and Rbm20 -/-mice, indicative of a cardiomyopathic phenotype ( Figure 1G through 1I). Surface ECGs showed a prolonged PR and heart rate-corrected QT interval in Rbm20 -/-mice, starting at 6 weeks of age, which remained until at least 25 weeks of age ( Figure 1J and 1K). No difference in QRS duration and RR interval were observed ( Figure I in the online-only Data Supplement). The differences between 6 and 8 weeks can be explained by growth and matu-ration of the mice. Rbm20 -/-hearts showed moderate fibrosis, as was evidenced by Sirius red-stained sections of the hearts of 25-week-old mice ( Figure 1L and 1M). The expression of collagen 1a1 and collagen 3a1 mRNA was consistently increased in Rbm20 -/-hearts ( Figure II in the online-only Data Supplement). In summary, Rbm20 KO mice develop cardiomyopathy and have ECG abnormalities, increased cardiac fibrosis, and disturbed splicing of previously described Rbm20 targets.
Rbm20 KO Mice Display Splicing Abnormalities in Ca
2+ -and Ion-Handling Genes
To uncover splicing targets of Rbm20 that could explain the increased risk of arrhythmias in RBM20 mutation carriers, we used next-generation RNA sequencing on WT and Rbm20 -/-mice, 25 weeks of age, and analyzed their transcriptomes on differential splicing events using DEXseq.
14 Gene ontology enrichment analysis on the differentially spliced genes revealed that genes involved in cardiac muscle contraction were enriched in the hearts of Rbm20 -/-mice (File II in the online-only Data Supplement). It is interesting to note that genes in the biological process of cardiac muscle contraction encompass 2 types of genes: sarcomeric genes, such as Ttn, Tnnt2, and Myh6/7, and Ca 2+ -and ion-handling genes, such as Slc8a1, RyR2, and CamkIIδ ( Figure 2A ). We validated the differential splicing events using end point reverse transcriptase polymerase chain reaction in WT, Rbm20
, and Rbm20
-/-mice, and were able to verify the splicing changes in CamkIIδ, RyR2, Scn5a (which encodes the cardiac Na + channel NaV1.5), and Cacna1c (which encodes the L-type calcium channel subunit CaV1.2) ( Figure 2B , Figure IIIA through IIIC in the online-only Data Supplement).
The atypical splicing of CamkIIδ in the Rbm20 KO hearts is particularly relevant for cardiomyocyte biology. CamkIIδ is a multifunctional Ser/Thr protein kinase and is an important regulator of excitation-contraction coupling by phosphorylation of its substrates phospholamban, the ryanodine receptor (RyR), and the L-type Ca 2+ channel (LTCC). [15] [16] [17] CamkIIδ exists in multiple isoforms in the adult heart, most notably δ-A, δ-B, δ-C, and δ-9. 18 In the healthy adult heart, the highest expressed isoforms are δ-B and δ-C, but loss of Rbm20 induced a switch toward the bigger δ-A and δ-9 mRNA isoforms ( Figure 2B ). The smallest isoform, δ-C, lacks all alternative exons, and is located in the cytoplasm, where it has been shown to phosphorylate RyR2 and phospholamban. 15 In the δ-B isoform, exon 14 with a functional nuclear localization signal is spliced into the transcript, thereby targeting CamkIIδ to the nucleus, where it specifically associates with histone deacetylases to regulate transcription. 19, 20 The δ-A isoform results from inclusion of exon 15 and 16, and is associated with the intercalated disc and T tubules, where Ca 2+ channels and activated CamKIIδs are concentrated. 16, 21 The exact function of δ-9 is currently unknown, but because it is the isoform that resembles δ-A the most (it only lacks exon 15), it likely fulfills a function similar to δ-A.
The nearly complete switch of CamKIIδ to the δ-A isoform led us to investigate the consequences of aberrant splicing on CamKIIδ expression and localization in the Rbm20 KO hearts. Western blotting further provided evidence of the isoform switch, because we Data are presented as mean±SD unless otherwise indicated. To test for statistically significant differences between the groups, the 2-tailed Student t test was used for continuous variables, and the Fisher exact test or χ 2 test was used for categorical variables. ACE indicates angiotensin-converting enzyme; ATII, angiotensin receptor II; BSA, body surface area; FH SCD, family history of sudden cardiac death <45 years; ICD, internal cardioverter defibrillator; LVEDD, left ventricular end-diastolic diameter; LVEDV, left ventricular end-diastolic volume; LVEDV index, left ventricular end-diastolic diameter indexed to body surface area; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; QTc, heart rate-corrected QT interval; VF, ventricular fibrillation; and VT, ventricular tachycardia. Figure 1 . Characterization of Rbm20 KO mice. A, Gene-targeting strategy of Rbm20 KO mice. Mice carrying the targeted allele were crossed with Flp mice to remove the LacZ and neomycin cassette and subsequently with CMV-Cre mice to genetically delete exon 4 and 5 of Rbm20. B through D, qPCR in hearts of wild-type (n=6), Rbm20 +/-(n=8), and Rbm20 -/-(n=8) mice of, respectively, Rbm20, ANF, and BNP. E, RT-PCR analysis of Ttn and Ldb3 splicing in the hearts of 3 wild-type, 3 Rbm20 +/-, and 3 Rbm20 -/-mice. Largest PCR product of TTN represents the inclusion of additional PEVK exons, indicative of the N2BA-G isoform. F, Heart weight/body weight ratios of wild-type (n=6), Rbm20 +/-(n=8), and Rbm20 -/-(n=8) mice. G through I, ECG analysis of wild-type (n=7), Rbm20 +/-(n=9), and Rbm20 -/-(n=8). J and K, Surface ECGs of wild-type (n=7), Rbm20 +/-(n=9), and Rbm20 -/-(n=8) mice. L, H&E and Picrosirius Red staining of wild-type, Rbm20
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, and Rbm20 -/-heart sections. M, Quantification of fibrosis in wild-type (n=6), Rbm20 +/-(n=6), and Rbm20 -/-(n=8) hearts. All analyses were done in 25-week-old mice. One-way ANOVA with least significance difference (LSD) post hoc correction was used to test for statistical significance. *P<0.05 versus wild-type. #P<0.05 versus Rbm20 +/-. ANF indicates atrial natriuretic factor; BNP, brain natriuretic factor; H&E, hematoxylin and eosin; HW/BW, heart weight/body weight; KO, knockout; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; PCR, polymerase chain reaction; qPCR, quantitative polymerase chain reaction; QTc, heart rate-corrected QT interval; and RT-PCR, reverse transcriptase polymerase chain reaction. Figure 2C , Figure IIIE in the onlineonly Data Supplement). We did not find a difference in overall mRNA expression of CamkIIδ in WT, Rbm20 +/-, and Rbm20
-/-mice ( Figure IIID in the online-only Data Supplement). We performed immunohistochemistry on sections of WT and Rbm20 -/-hearts and found that CamkIIδ colocalizes with the LTCC in the T tubules, as indicated by costaining with Cacnb1 ( Figure 2D, Figure IV in the online-only Data Supplement). We did not find increased CamkIIδ localization in the T tubules in Rbm20 -/-hearts in comparison with WT hearts, but this difference might be subtle and not readily identifiable with immunostainings. It is interesting to note that we detected increased expression of CamKIIδ in the intercalated discs of Rbm20 -/-cardiomyocytes, again indicating a switch to the δ-A isoform. 21 Because the switch in CamkIIδ isoform could potentially impact phosphorylation targets of CamkIIδ, we performed Western blotting for phosphorylated RyR2 (at serine 2815) and A, Two biological categories were identified in the most enriched process (cardiac muscle contraction) after gene ontology enrichment analysis (DAVID) of differentially spliced genes in Rbm20 KO hearts: sarcomeric genes and ion-handling genes. *Cacna1c splicing changes did not pass the adjusted P value in this n=3 experiment, but has previously been shown to be an Rbm20 target. , and Rbm20 -/-mice. D, Immunohistochemistry of CamkIIδ (red) in hearts of wild-type and Rbm20 -/-mice. Cacnb2 (green) was used to stain LTCCs, and DAPI (blue) was used to stain nuclei. Scale bar=20 μm. The analyses were done on hearts of 25-week-old mice. E, qPCR of Rbm20 mRNA levels in NRCM 48 hours after GapmeR-mediated knockdown of Rbm20. F, RT-PCR of Ttn, CamkIIδ, and RyR2 splicing after Rbm20 knockdown in NRCM. G, DeltaPSI plots of CamkIIδ and RyR2 of a patient with DCM (black line) and an RBM20 mutation carrier (red line) in comparison with the mean of 10 healthy control hearts. The two-tailed Student t test was used to test for statistical significance. DAPI indicates 4ʹ,6-diamidino-2-phenylindole; DCM, dilated cardiomyopathy; KD, knockdown; KO, knockout; LTCC, L-type Ca 2+ channel; NRCM, neonatal rat cardiomyocyte; PSI, percentage spliced in; qPCR, quantitative polymerase chain reaction; RT-PCR, reverse transcriptase polymerase chain reaction; and SCR, scrambled.
phosphorylated Cacnb2 (at threonine 498) in Rbm20 -/-hearts. In both cases, we did not observe a difference in phosphorylation status at these specific amino acids ( Figure V in the online-only Data Supplement). The differential splicing event in RyR2 involves inclusion of a 24-bp exon, which targets RyR2 to the nucleus instead of the SR, which may interfere with proper Ca 2+ handling. 22 The splicing change that we observed in Scn5a represents alternative first exon usage with yet unknown significance. 23 The splicing change in Cacna1c, which encodes a subunit of the LTCC, in Rbm20 -/-hearts represents the inclusion of exon 9*, and this splicing event has been associated with hyperpolarization of the LTCC. 24 With respect to the differential splicing events in Slc8a1 (Ncx1), we found increased inclusion of exon 2A, indicative of increased expression of the Na + /Ca 2+ exchanger 1.1 splice variant. 25 The increased expression of the Na + /Ca 2+ exchanger 1.1 splice variant could indicate that Na + -dependent inactivation of Na + /Ca 2+ exchanger is reduced, 25 but the functional consequences in Rbm20 KO hearts are unclear.
To rule out that the differential splicing events are not secondary to the DCM, but attributable to the loss of Rbm20, we used GapmeRs to knock down Rbm20 in neonatal rat cardiomyocytes, which resulted in a ≈80% decrease in Rbm20 mRNA expression ( Figure 2E ). Using end point reverse transcriptase polymerase chain reaction, we observed similar splicing changes in Ttn, CamkIIδ, and RyR2 as in the Rbm20 KO hearts (Figure 2F ). These in vitro data indicate that Rbm20 directly regulates alternative splicing of TTN, CamKIIδ, and RyR2 and that these isoform switches are not secondary to the DCM.
To investigate whether these Rbm20-dependent splicing changes also occur in human RBM20 mutation carriers, we made use of an RNA-sequencing data set of a previously described patient who had DCM with a heterozygous RBM20 (p.E913K) mutation that we compared with a patient with idiopathic DCM and 10 healthy individuals. 26, 27 We calculated the percentage spliced in of the alternative exons and found that, also in this RBM20 mutation carrier, but not in the patient with DCM, alternative splicing of CAMK2D and RYR2 was similarly affected ( Figure 2G , Figure VI in the online-only Data Supplement). We did not observe splicing differences in SCN5A and CACNA1C in the patient with RBM20 in comparison with the patient with DCM (data not shown).
With respect to the CAMK2D splicing in the human RBM20 mutation carrier, it is remarkable that δ-9 was greatly induced, and not δ-A, as we found in the Rbm20 KO mice and in neonatal rat cardiomyocytes with reduced Rbm20 levels. Indeed, it was shown earlier that exon 15 (included in δ-A, but excluded in δ-9) is hardly expressed in the human heart. 5, 6 In conclusion, these data reveal splicing abnormalities in Ca 2+ -and ion-handling genes such as CamkIIδ and RyR2 after loss of Rbm20 in humans, rats, and mice.
I Ca,L Is Increased in Rbm20 KO Myocytes
To investigate whether the splicing abnormalities in CamKIIδ and Cacna1c in Rbm20 -/-hearts would affect I Ca,L and APs, we performed patch-clamp electrophysiological studies in isolated cardiomyocytes of 8-to 12-week-old mice, representing the early phase in the development of the cardiomyopathy. We found that the AP duration at 90% of repolarization was prolonged in Rbm20 -/-cardiomyocytes by ≈50% (Figure 3A and 3B) . The upstroke of the AP, as indicated by the maximum upstroke velocity and AP amplitude, and the resting membrane potential were not significantly different ( Figure 3C and 3D) . Because the AP duration is importantly regulated by I Ca,L and because the isoform switch of CamkIIδ is expected to increase the activity of the LTCC, we recorded I Ca,L . Figure 3E shows representative I Ca,L recordings on a depolarizing step from -60 to 0 mV, and the right graph shows the same recordings but scaled to the I Ca,L of WT cardiomyocytes. I Ca,L was significantly larger in Rbm20 -/-cardiomyocytes, and inactivation was faster, as analyzed with biexponential fits. Time constants of both fast and slow inactivation were significantly lower in Rbm20 
Rbm20 KO Cardiomyocytes Exhibit
ORIGINAL RESEARCH ARTICLE
peak amplitude was increased ≈3-fold (peak amplitude WTvsHETvsKO , 101±10.5 versus 333.9±60.8 versus 308.9±58.8 nmol/L) in Rbm20 +/-and Rbm20 -/-cardiomyocytes ( Figure 4A through 4C) . Next, we examined SR Ca 2+ content by rapid cooling and found that it was increased ≈3.5-fold in Rbm20 +/-and Rbm20 increase the open probability of the RyR channels, resulting in an increase of spontaneous SR Ca 2+ releases, which in turn can trigger delayed afterdepolarizations that are proarrhythmic. 28 To examine spontaneous SR Ca 2+ releases, we stopped stimulation (6 Hz) of cardiomyocytes, after which spontaneous activity was recorded for 10 seconds. At baseline, both Rbm20 +/-and Rbm20 -/-cardiomyocytes showed more spontaneous Ca 2+ releases than WT cardiomyocytes, and this effect was exacerbated after application of 50 nmol/L noradrenaline ( Figure 4E , representative traces in Figure IX in the online-only Data Supplement).
In conclusion, our data show that Rbm20 KO cardiomyocytes display Ca 2+ overload, increased SR Ca 2+ content, and more spontaneous Ca 2+ releases, especially after β-adrenergic stimulation. It is interesting to note that Ca 2+ handling was as severely affected in Rbm20
+/-as in the Rbm20 -/-cardiomyocytes.
Inhibition of I Ca,L With Verapamil Decreases Proarrhythmic Spontaneous Ca 2+ Releases
Because we suspect that the increased I Ca,L underlies the increased intracellular Ca 2+ levels, the SR Ca 2+ overload, and the spontaneous Ca 2+ releases in the Rbm20 KO cells, we hypothesized that inhibiting I Ca,L with verapamil, a well-known LTCC antagonist, would decrease the number of spontaneous Ca 2+ releases. We incubated Rbm20
-/-cardiomyocytes with 1 µmol/L verapamil, a concentration that has been shown to decrease I Ca,L by ≈30%, 29 and again recorded spontaneous Ca 2+ releases. It is striking that incubation of Rbm20 -/-cardiomyocytes with verapamil decreased the number of spontaneous Ca 2+ releases after the addition of noradrenaline to WT levels ( Figure 4E , Figure IX in the online-only Data Supplement). These data indicate that the increased I Ca,L , at least in part, contributes to proarrhythmic SR Ca 2+ releases in Rbm20 -/-cardiomyocytes. Moreover, our results indicate that treatment of RBM20 mutation carriers with the LTCC antagonist verapamil might prove beneficial to decrease the number of malignant ventricular arrhythmias that RBM20 mutation carriers experience. Figure 5 depicts the proposed model of how Rbm20 deficiency leads to proarrhythmic spontaneous Ca 2+ releases.
DISCUSSION
This study shows that RBM20 mutation carriers have more severe ventricular arrhythmias than TTN mutation carriers, despite equally severe DCM. This suggests that other mechanisms besides missplicing of TTN may contribute to the aggressive clinical course of RBM20-induced DCM. We addressed whether this relates to missplicing of Ca 2+ -handling genes. We investigated this in Rbm20 KO mice, and revealed that Rbm20 KO cardiomyocytes have severely disturbed Ca 2+ handling, with increased Ca 2+ transients, increased diastolic Ca 2+ , increased SR Ca 2+ , and more spontaneous Ca 2+ releases from the SR. Furthermore, electrophysiological studies revealed that the AP is prolonged in Rbm20 KO cardiomyocytes. Alternative splicing changes in 2 Rbm20 target genes, ie, CamkIIδ and Cacna1c, pointed us to the LTCC as the potential culprit for the observed Ca 2+ overload in Rbm20 KO cardiomyocytes. We recorded I Ca,L and show that LTCC activity is substantially increased in Rbm20 KO cardiomyocytes. Moreover, blockade of I Ca,L with the LTCC antagonist verapamil completely rescued the noradrenaline-induced spontaneous Ca 2+ releases from the SR, indicating that increased I Ca,L density enhances Ca 2+ influx and, in turn, causes intracellular and SR Ca 2+ overload in Rbm20 KO cells ( Figure 5 ). Our data indicate that this function of Rbm20 likely underlies the increased risk of arrhythmias in RBM20 mutation carriers, and, therefore, this study provides new avenues to investigate the treatability of arrhythmias in RBM20 mutation carriers. Furthermore, our findings underscore the necessity for careful clinical monitoring of potential electric disturbances and cardiac arrhythmias in RBM20 mutation carriers, even during the early stages of the disease.
It has been proposed that regulating TTN splicing, by means of modulating RBM20 levels, could be beneficial for the heart, especially in the setting of heart failure with preserved ejection fraction. 13, 30, 31 Methawasin et al 13 have shown that, in heterozygous Rbm20 KO mice, beneficial effects of more compliant Ttn (ie, reduction in diastolic chamber stiffness) dominate over disadvantageous effects (ie, depressed end-systolic elastance). In a mouse model of heart failure with preserved ejection fraction, these beneficial effects were even more pronounced. 30 However, our current study reveals that, although it may be advantageous to modulate Ttn splicing to decrease passive stiffness in certain types of heart disease where passive stiffness is increased, the effect on other Rbm20 targets must be carefully evaluated. The fact that a 50% reduction in Rbm20 levels (ie, in Rbm20 +/-mice) already induces a clear shift in CamkIIδ toward the δ-A and δ-9 isoform, with concomitant Ca 2+ -handling abnormalities, argues for careful examination of using RBM20 modulation as a therapeutic option. The exquisite sensitivity of isoform expression by levels of RBM20 was also observed in the study by Maatz et al, 6 who showed that RBM20 levels closely correlate with the extent of splicing in RBM20 targets such as TTN, CAMK2D, RYR2, and LDB3.
The observed increase in LTCC density and intracellular Ca 2+ overload in Rbm20 KO hearts cannot be explained by an underlying cardiomyopathy because it sharply contrasts to what is generally observed in DCM or heart failure, where LTCC density is either unaltered or reduced, and intracellular Ca 2+ and SR Ca 2+ content are decreased. 32, 33 Therefore, it is very unlikely that the Ca 2+ -handling abnormalities in the Rbm20 KO hearts are secondary to the DCM, but rather are directly caused by the loss of Rbm20 and its effects on splicing of Ca 2+ -handling genes. We show that I Ca,L inhibition with verapamil in Rbm20 -/-cardiomyocytes decreases the number of proarrhythmic Ca 2+ releases, and this suggests that verapamil may be used as therapy for RBM20 mutation carriers to reduce their arrhythmia burden. Verapamil is a class IV antiarrhythmic agent,
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and acts by blocking voltage-dependent Ca 2+ channels. It is currently used to treat hypertension and migraines, but is contraindicated in the treatment of general heart failure. This is because verapamil has a negative inotropic effect, because it lowers intracellular Ca 2+ , which in most forms of heart failure is already decreased. 32, 33 In addition, the few small clinical trials in patients with heart failure that have been performed have not shown a beneficial effect of this drug. 34 However, because in heart failure cardiac Ca 2+ cycling is generally diminished, it is not surprising that verapamil was not found to have a beneficial effect (it could even worsen cardiac function by further decreasing intracellular Ca 2+ and thereby contractility). Because cardiac Ca 2+ transients are increased in RBM20 mutation carriers, treatment with verapamil could be beneficial for this subgroup of patients with heart failure. Besides verapamil, other ways to therapeutically decrease intracellular Ca 2+ and SR Ca 2+ content might be worthwhile to explore in RBM20 mutation carriers as well.
In recent years, the importance of alternative splicing, and how abnormal splicing contributes to heart disease, has become increasingly clear. 35, 36 Several splicing factors, including Rbm20, Rbm24, Rbfox, and SF3B1, were shown to have critical roles in the developing or adult heart. 5, [37] [38] [39] It is interesting to note that the isoform switch in CamkIIδ to the δ-A and δ-9 isoform that we observed in the Rbm20 KO mice is also seen after cardiac-specific deletion of yet another splicing factor, ASF/SF2, leading to similar changes in cardiac Ca 2+ handling. 21 Furthermore, the same study also provided evidence that transgenic overexpression of CamkIIδ-A alone phenocopies the Ca 2+ -handling defects observed in the ASF/SF2 KO mice, indicating that the shift in CamkIIδ isoforms largely underlies the Ca 2+ -handling defects in the ASF/ SF2 KO 21 . It is surprising that a complete loss of CamkIIδ in myocytes also results in an increase in I Ca,L , albeit to a lesser extent (15%-18% in CamkIIδ KO versus 82% in Rbm20 KO). 40 However, opposite to what is seen in ASF/ SF2 KO (and in Rbm20 KO), CamkIIδ KO cardiomyocytes have decreased intracellular Ca 2+ and SR Ca 2+ content. Overall, these studies show that changes in CamkIIδ isoforms are more detrimental than complete loss of Camk IIδ. 15, 18, 21, 41, 42 In particular, the observation that transgenic overexpression of the δ-A isoform of CamkIIδ phenocopies the Ca 2+ -handling defects that we observed in the Rbm20 KO hearts, suggests that the isoform switch in CamKIIδ in Rbm20 KO hearts is largely responsible for the Ca 2+ defects. We did not observe increased phosphorylation of Thr498 in Cacnb2 (a reported CamKIIδ target 16 ) in Rbm20 KO hearts, indicating that phosphorylation of this specific residue is not the reason the LTCC is more active. Therefore, how increased expression of CamkIIδ-A increases I Ca,L , be it through increased LTCC phosphorylation 16, 17 or a different mechanism, remains to be investigated. Naturally, we cannot exclude the contribution of Rbm20-dependent splicing events in RyR2, Cacna1c, Ncx1, and Scn5a to the Ca 2+ phenotype, but the function of these splice isoforms is less well studied. It is known, for example, that inclusion of the Rbm20-dependent 24-bp exon in RyR2 targets RyR2 to an intranuclear Golgi apparatus, instead of the SR. 22 Reduced RyR2 in the SR could also impact cardiac Ca 2+ handling, but the contribution of this differential splice event in Rbm20 KO cardiomyocytes remains to be determined. The same holds true for the splicing changes in Cacna1c, Ncx1, and Scn5a, because these could also impact Ca 2+ handling, either directly or indirectly. However, we did not observe hyperpolarization of the LTCC because of the increased inclusion of exon 9* in Cacna1c, as was previously reported, 24 indicating that this specific splicing event does not affect the LTCC in mouse cardiomyocytes, or that the increase was not sufficient to induce the hyperpolarization ( Figure 3G ).
Familial DCM is often caused by mutations in sarcomeric genes, 4 but in RBM20 mutation carriers, the DCM is caused by a dysfunctional splicing factor, which makes the disease phenotype likely much more complex. Dysfunctional RBM20 affects a multitude of genes, such as sarcomeric and Ca 2+ -handling genes, which together are responsible for the disease phenotype in RBM20 mutation carriers. In that sense, it is likely that the disease (and arrhythmogenic) phenotype is only partly explained by the CamkIIδ-LTCC pathway, and that other factors also contribute. The splicing changes in CamkIIδ likely also affect other target proteins, such as phospholamban or RyR2, and, although we did not observe a difference in CamkII-dependent phosphorylation of RyR2 on S2815, we cannot rule out that the altered phosphorylation status of these targets might have contributed to the calcium disturbances. In addition, loss of the nuclear CamKIIδ-B isoform in the Rbm20 KO hearts may lead to hampered nuclear export of histone deacetylases, thereby potentially repressing MEF2-dependent gene expression.
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Limitations
There are some limitations to this study. First, with regard to the clinical data, it must be noted that we had access to only a limited number of RBM20 and TTN mutation carriers, and, therefore, these results can merely serve as an indication of the arrhythmia burden of these 2 groups of patients with DCM. It will be important to validate these findings in larger cohorts. In addition, although it is likely that TTN is misspliced in the RBM20 mutation carriers, we do not have access to their cardiac tissue, and could not validate that TTN is similarly affected in all patients. Therefore, we need to be cautious about the conclusions drawn from this table. Nevertheless, the table shows that dysfunctional TTN does not lead to an arrhythmogenic phenotype, whereas dysfunctional RBM20 does. In addition, the occurrence of sustained ventricular tachycardia/ventricular fibrillation in 50% of RBM20 mutation carriers indicates that RBM20 mutations carriers have an arrhythmia burden comparable to LMNA mutation carriers, which are known to have an arrhythmogenic phenotype. 4 Second, there are differences between the human RBM20 mutation carriers and our Rbm20 KO mouse model. The mouse model represents a true loss of function (and 50% Rbm20 protein levels in the heterozygotes), whereas most human RBM20 mutation carriers have a missense mutation in the RNA-binding region in only 1 allele. It is conceivable that these missense mutations do not lead to protein instability or nonsense-mediated decay, but rather to disruption of RBM20 binding to RNA through potentially dominant-negative mechanisms. Mouse models in which specific human RBM20 mutations are introduced are awaited with great interest to further study the underlying pathophysiological mechanism. Third, the electrophysiological properties of human and mouse cardiomyocytes are not entirely similar. For example, the differences in potassium currents between human and mouse may explain why we did not observe heart rate-corrected QT interval prolongation in RBM20 mutation carriers, whereas we did see heart rate-corrected QT interval prolongation in Rbm20 -/-mice. 43 However, the basic calcium-handling machinery is comparable, and human induced pluripotent stem cell-derived cardiomyocytes derived from an RBM20 mutation carrier show similar calcium-handling abnormalities. 9 In conclusion, much of the research regarding RBM20-induced cardiomyopathy has focused on TTN, but aberrant TTN splicing only partly explains the clinical characteristics of RBM20 mutation carriers. Here, we provide evidence that Rbm20 controls Ca 2+ handling by regulating the activity of I Ca,L . This function of Rbm20 likely underlies the increased risk of arrhythmias in RBM20 mutation carriers, and therefore we provide proof-of-concept of a potential therapy to relieve RBM20 mutation carriers from their arrhythmia burden by treatment with LTCC antagonists.
